Telix Pharmaceuticals Limited Sponsored ADR TLX 深 沪
等待开盘 05-20 09:30:00 美东时间
10.17
-0.110
-1.07%
华盛通- 最 高10.30
- 今 开10.17
- 成交量 8.11万股
- 最 低 10.12
- 昨 收 10.28
- 总市值 34.45亿
- 52周最高 18.49
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 6.28
- 委 比 -56.58%
- 总股本 3.39亿
- 历史最高 30.36
- 量 比 0.84
- 振 幅 1.75%
- 历史最低 6.28
- 每 手 1
- 风险率 3.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Regeneron Stock Sinking Monday?
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
05-18 18:28
Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
05-15 18:33
Telix Pharmaceuticals' TLX250-Px PET/CT Demonstrates High Predictive Accuracy Across All Renal Cancer Subtypes In Phase 3 ZIRCON Trial Analysis
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology1, demonstrating that TLX250-Px
05-05 05:03
Telix Pharmaceuticals To Present Safety And Tolerability Data From The ProstACT Global Phase 3 Study At ASCO 2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that safety and tolerability data from the ProstACT Global Phase 3
04-22 04:52
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.
04-14 20:02
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs
Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to $2.1 billion and royalties.
04-13 20:38
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
FDA accepts Telix NDA for Pixclara for brain cancer imaging, analysts see confidence rebuild amid steady sales growth.
04-10 21:15
美股夜盘 | Telix Pharmaceuticals Limited Sponsored ADR涨16.33%，最新股价11.4美元
Telix Pharmaceuticals Limited Sponsored ADR涨16.33%，报11.4美元
04-10 15:43
美股夜盘 | Telix Pharmaceuticals Limited Sponsored ADR涨10.00%，最新股价10.78美元
Telix Pharmaceuticals Limited Sponsored ADR涨10.00%，报10.78美元
04-10 12:22
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
